Are you over 18 and want to see adult content?
More Annotations
A complete backup of cookincanuck.com
Are you over 18 and want to see adult content?
A complete backup of australiangeographic.com.au
Are you over 18 and want to see adult content?
A complete backup of rightpronunciation.com
Are you over 18 and want to see adult content?
A complete backup of telegraphjournal.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://mshare.xyz/file/dodbQQJ
Are you over 18 and want to see adult content?
A complete backup of https://zh-tw.facebook.com/KFMza/posts/
Are you over 18 and want to see adult content?
A complete backup of https://www.urajp.eu/category/urahon/page/939/
Are you over 18 and want to see adult content?
A complete backup of http://buntya.com/tdd/website-of-Azerbaijan/
Are you over 18 and want to see adult content?
A complete backup of https://noveladowns.blogspot.com/p/parceria.html
Are you over 18 and want to see adult content?
A complete backup of http://finance.sina.com.cn/stock/usstock/
Are you over 18 and want to see adult content?
A complete backup of https://gemidos.tv/trans/
Are you over 18 and want to see adult content?
A complete backup of https://www.keyfora.com/site/unblocktorrent.com
Are you over 18 and want to see adult content?
A complete backup of https://www.aliantegaming.com/
Are you over 18 and want to see adult content?
Text
healthcare system.
NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May. NUMINUS | NUMINUS WELLNESS Q2 2021 RESULTS HIGHLIGHTED BY Q2 2021 Highlights: Achieved cash balance of $28.5 million as at February 28, 2021. Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options. Realized net loss of $4.2 million compared to $2.1 million in Q2 2020. Reported revenue of $231,507 compared to $259,489 in Q2 2020. NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS COMMENCES PSILOCYBE MUSHROOM CULTIVATION AT ITS Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory. Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies. VANCOUVER, BC, Sept. 24, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a
NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to NUMINUS | DR. DEVON CHRISTIE, MD CCFP RTC IFMCP, JOINS VANCOUVER (June 3, 2020)—Dr. Evan Wood, Numinus Chief Medical Officer, today announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX-V: NUMI) — another key step in the Company’s evolution as a leader in theadvancement of
HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | HOMEPAGELABHEALTHTEAMINVESTORSLEARNCONTACT Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May. NUMINUS | NUMINUS WELLNESS Q2 2021 RESULTS HIGHLIGHTED BY Q2 2021 Highlights: Achieved cash balance of $28.5 million as at February 28, 2021. Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options. Realized net loss of $4.2 million compared to $2.1 million in Q2 2020. Reported revenue of $231,507 compared to $259,489 in Q2 2020. NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS COMMENCES PSILOCYBE MUSHROOM CULTIVATION AT ITS Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory. Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies. VANCOUVER, BC, Sept. 24, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a
NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to NUMINUS | DR. DEVON CHRISTIE, MD CCFP RTC IFMCP, JOINS VANCOUVER (June 3, 2020)—Dr. Evan Wood, Numinus Chief Medical Officer, today announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX-V: NUMI) — another key step in the Company’s evolution as a leader in theadvancement of
HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | LEARN OVERVIEW Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness. Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms. NUMINUS | NUMINUS WELLNESS Q2 2021 RESULTS HIGHLIGHTED BY Q2 2021 Highlights: Achieved cash balance of $28.5 million as at February 28, 2021. Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options. Realized net loss of $4.2 million compared to $2.1 million in Q2 2020. Reported revenue of $231,507 compared to $259,489 in Q2 2020. NUMINUS | TEAM OVERVIEW This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.”NUMINUS | CONTACT
This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS FIRST CANADIAN PUBLIC COMPANY TO Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms. Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility.. VANCOUVER, BC, Oct. 22, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on NUMINUS RECEIVES HEALTH CANADA LICENCE AMENDMENT TO Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms. Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence. VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the “Company”) has received Health Canada approval to amend the NUMINUS | NUMINUS ANNOUNCES CLOSING OF $17 MILLION BOUGHT This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS WELLNESS AND OPTIMI HEALTH SUBMIT ALL Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application. Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial. VANCOUVER (May 11, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe NUMINUS | NUMINUS BUILDS ON STRONG MAPS PHASE 3 TRIAL Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD. Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD - a major contribution to a growing body of evidence supporting this treatment. NUMINUS | HOMEPAGELABHEALTHTEAMINVESTORSLEARNCONTACT Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May. NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenueNUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS | NUMINUS ANNOUNCES COMPASSIONATE ACCESS TRIAL OF… Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders. Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders NUMINUS RECEIVES HEALTH CANADA LICENCE AMENDMENT TO Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms. Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence. VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the “Company”) has received Health Canada approval to amend the NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | HOMEPAGELABHEALTHTEAMINVESTORSLEARNCONTACT Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May.NUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS | NUMINUS ANNOUNCES COMPASSIONATE ACCESS TRIAL OF… Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders. Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders NUMINUS RECEIVES HEALTH CANADA LICENCE AMENDMENT TO Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms. Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence. VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the “Company”) has received Health Canada approval to amend the NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | LEARN OVERVIEW Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness. Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms.NUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | TEAM OVERVIEW This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS WELLNESS Q2 2021 RESULTS HIGHLIGHTED BY Q2 2021 Highlights: Achieved cash balance of $28.5 million as at February 28, 2021. Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options. Realized net loss of $4.2 million compared to $2.1 million in Q2 2020. Reported revenue of $231,507 compared to $259,489 in Q2 2020.NUMINUS | CONTACT
This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS WELLNESS AND OPTIMI HEALTH SUBMIT ALL Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application. Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial. VANCOUVER (May 11, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe NUMINUS | NUMINUS ANNOUNCES CLOSING OF $17 MILLION BOUGHT Vancouver, British Columbia, December 29, 2020, Numinus Wellness Inc. (“ Numinus ” or the “ Company ”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that ithas closed its
NUMINUS | NUMINUS CONGRATULATES MAPS ON PHASE 3 CLINICAL Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD. Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada. VANCOUVER (May 10, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company NUMINUS | NUMINUS BUILDS ON STRONG MAPS PHASE 3 TRIAL Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD. Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD - a major contribution to a growing body of evidence supporting this treatment. TO HELP PEOPLE HEAL AND BE WELL DEVELOPING & DELIVERING 3 Unmet Need Mental health is a $100B+ industry,¹ and current treatments are often costly and ineffective Breakthrough Potential Psychedelics are becoming more accepted, validated by academic NUMINUS | HOMEPAGELABHEALTHTEAMINVESTORSLEARNCONTACT Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May. NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenueNUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS | NUMINUS ANNOUNCES COMPASSIONATE ACCESS TRIAL OF… Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders. Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders NUMINUS RECEIVES HEALTH CANADA LICENCE AMENDMENT TO Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms. Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence. VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the “Company”) has received Health Canada approval to amend the NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | HOMEPAGELABHEALTHTEAMINVESTORSLEARNCONTACT Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 NUMINUS | NUMINUS CLINICS Numinus supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of thehealthcare system.
NUMINUS | NEWS OVERVIEW News Releases. 13 May. FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa. 13 May. Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation. 11 May. FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement. 11 May. NUMINUS | INVESTOR OVERVIEW Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenueNUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | NUMINUS ANNOUNCES LISTING OF WARRANTS Numinus Announces Listing of Warrants. VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted NUMINUS | NUMINUS ANNOUNCES COMPASSIONATE ACCESS TRIAL OF… Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders. Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders NUMINUS RECEIVES HEALTH CANADA LICENCE AMENDMENT TO Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms. Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence. VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the “Company”) has received Health Canada approval to amend the NUMINUS | NUMINUS AND MAPS PUBLIC BENEFIT CORPORATION Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial. First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to HCMINISTER.MINISTRESC@CANADA TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians.In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). NUMINUS | LEARN OVERVIEW Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness. Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms.NUMINUS | LAB
Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the NUMINUS | TEAM OVERVIEW This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS WELLNESS Q2 2021 RESULTS HIGHLIGHTED BY Q2 2021 Highlights: Achieved cash balance of $28.5 million as at February 28, 2021. Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options. Realized net loss of $4.2 million compared to $2.1 million in Q2 2020. Reported revenue of $231,507 compared to $259,489 in Q2 2020.NUMINUS | CONTACT
This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” NUMINUS | NUMINUS WELLNESS AND OPTIMI HEALTH SUBMIT ALL Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application. Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial. VANCOUVER (May 11, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe NUMINUS | NUMINUS ANNOUNCES CLOSING OF $17 MILLION BOUGHT Vancouver, British Columbia, December 29, 2020, Numinus Wellness Inc. (“ Numinus ” or the “ Company ”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that ithas closed its
NUMINUS | NUMINUS CONGRATULATES MAPS ON PHASE 3 CLINICAL Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD. Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada. VANCOUVER (May 10, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company NUMINUS | NUMINUS BUILDS ON STRONG MAPS PHASE 3 TRIAL Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD. Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD - a major contribution to a growing body of evidence supporting this treatment. TO HELP PEOPLE HEAL AND BE WELL DEVELOPING & DELIVERING 3 Unmet Need Mental health is a $100B+ industry,¹ and current treatments are often costly and ineffective Breakthrough Potential Psychedelics are becoming more accepted, validated by academic__
__
* clinics
* lab
* team
* investors
* news
* careers
* contact
PSYCHEDELIC-ASSISTED PSYCHOTHERAPY TO HEAL AND BE WELL. Safe, legal access is going to become increasingly available for a range of conditions, including depression, PTSD & substance usedisorders.
MENTAL HEALTH CARE IS BROKEN, BUT IT CAN BE FIXED. We envision a world where all people are empowered to discover healing and wellness. That’s why we’re creating solutions to develop and deliver cutting-edge psychedelic-assisted psychotherapy and transform the mental health landscape. NUMINUS SUPPORTS ACCESS TO PSYCHEDELIC-ASSISTED PSYCHOTHERAPY THROUGH KETAMINE-ASSISTED PSYCHOTHERAPY, SPECIAL ACCESS & COMPASSIONATE ACCESSTRIALS.
Starting in Vancouver and expanding to Montreal, Numinus is proud to partner with practitioners in providing clients with access to psychedelic-assisted psychotherapy. With our acquisition of Mindspace,
a Quebec-based psychedelic programming leader, Numinus now supports practitioners across 3 clinic locations. Numinus supports access to psychedelic-assisted psychotherapy throughthese pathways:
KETAMINE-ASSISTED PSYCHOTHERAPY Mindspace practitioners in Montreal are offering KAP, which can be prescribed to address treatment-resistant depression. SPECIAL ACCESS FOR PSILOCYBIN & MDMA Pending approval of regulatory change, Numinus intends to support practitioners in helping their patients navigate possible Special Access to psychedelic-assisted therapies for a range of conditions noting that this program is for patients with potentially life threatening conditions. COMPASSIONATE ACCESS TRIALS FOR PSILOCYBIN & MDMA Numinus is undertaking two compassionate access clinical trials for psilocybin and MDMA, which will be conducted in our Vancouver clinic. Learn more about Numinus’s Clinics here.
TRANSFORMATIVE CHANGE IS NEEDED971 million
People worldwide currently suffer from a mental disorder450,000
People worldwide died from drug use in 20151 in 2
Canadians will be affected by mental health issues by the age of 404,000
Canadians die by suicide per year – almost 11 suicides per day1 in 2
Canadians receive inadequate care when experiencing a depressiveepisode
1 in 5
Canadians suffer from addiction in any given year1 in 11
Canadian adults will suffer PTSD in their lifetime$51B
The estimated annual economic burden of mental illness in CanadaINVESTORS
NUMI Quotes by
TradingView
INVESTOR PRESENTATIONNEWS RELEASES
*
*
*
*
GET THE LATEST UPDATE*
Submit
Please enter your email address This website contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. 2021 Numinus. All rights reserved.* Privacy Notice
* Terms of Service
* Forward Looking Statements✕
* clinics
* lab
* team
* investors
* news
* careers
* contact
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0